Drug intelligence / Profile preview

INH002

Development stage: Preclinical
Lead developer: Innorna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

INH002 is an early-stage preclinical mRNA-based drug candidate being developed by InnoRNA Biotech in partnership with BeOne. The program utilizes InnoRNA's proprietary lipid nanoparticle (LNP) delivery platform to deliver messenger RNA (mRNA) for an undisclosed therapeutic indication. As of early 2026, the specific molecular target and mechanism of action remain proprietary and undisclosed. The candidate is part of InnoRNA's broader pipeline of mRNA-LNP therapeutics and vaccines, leveraging their specialized delivery technology to address unmet medical needs.

Beyond the preview

Go deeper on INH002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INH002.

Explore the full profile